Bloomberg Intelligence cover image

Novo Halves Ozempic Price to $499 a Month For Those Paying Cash

Bloomberg Intelligence

00:00

Evaluating Compounded Drugs Against Established Medications

This chapter analyzes the effectiveness of compounded drugs such as HIMS and HERS in relation to standard GLP medications, highlighting concerns over their FDA approval and safety. It also discusses market dynamics affecting Eli Lilly amidst competition in the weight loss pharmaceutical sector.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app